Hypomethylating agents and chemotherapy in MDS
Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Adès, Lionel [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations - 2012transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:26 ; year:2013 ; number:4 ; pages:411-419 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.beha.2013.09.010 |
|---|
| Katalog-ID: |
ELV038619857 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV038619857 | ||
| 003 | DE-627 | ||
| 005 | 20230625222746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.beha.2013.09.010 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013005000001.pica |
| 035 | |a (DE-627)ELV038619857 | ||
| 035 | |a (ELSEVIER)S1521-6926(13)00058-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 590 |q VZ |
| 082 | 0 | 4 | |a 070 |a 004 |q VZ |
| 084 | |a LING |q DE-30 |2 fid | ||
| 084 | |a 54.00 |2 bkl | ||
| 084 | |a 53.71 |2 bkl | ||
| 100 | 1 | |a Adès, Lionel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypomethylating agents and chemotherapy in MDS |
| 264 | 1 | |c 2013transfer abstract | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). | ||
| 520 | |a Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). | ||
| 650 | 7 | |a hypomethylating agents |2 Elsevier | |
| 650 | 7 | |a decitabine |2 Elsevier | |
| 650 | 7 | |a chemotherapy |2 Elsevier | |
| 650 | 7 | |a azacitidine |2 Elsevier | |
| 700 | 1 | |a Santini, Valeria |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |t A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations |d 2012transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV026207648 |
| 773 | 1 | 8 | |g volume:26 |g year:2013 |g number:4 |g pages:411-419 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.beha.2013.09.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-LING | ||
| 912 | |a SSG-OPC-BBI | ||
| 936 | b | k | |a 54.00 |j Informatik: Allgemeines |q VZ |
| 936 | b | k | |a 53.71 |j Theoretische Nachrichtentechnik |q VZ |
| 951 | |a AR | ||
| 952 | |d 26 |j 2013 |e 4 |h 411-419 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
l a la |
|---|---|
| matchkey_str |
adslionelsantinivaleria:2013----:yoehltnaetadhmt |
| hierarchy_sort_str |
2013transfer abstract |
| bklnumber |
54.00 53.71 |
| publishDate |
2013 |
| allfields |
10.1016/j.beha.2013.09.010 doi GBVA2013005000001.pica (DE-627)ELV038619857 (ELSEVIER)S1521-6926(13)00058-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Adès, Lionel verfasserin aut Hypomethylating agents and chemotherapy in MDS 2013transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). hypomethylating agents Elsevier decitabine Elsevier chemotherapy Elsevier azacitidine Elsevier Santini, Valeria oth Enthalten in Elsevier A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV026207648 volume:26 year:2013 number:4 pages:411-419 extent:9 https://doi.org/10.1016/j.beha.2013.09.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 26 2013 4 411-419 9 045F 610 |
| spelling |
10.1016/j.beha.2013.09.010 doi GBVA2013005000001.pica (DE-627)ELV038619857 (ELSEVIER)S1521-6926(13)00058-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Adès, Lionel verfasserin aut Hypomethylating agents and chemotherapy in MDS 2013transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). hypomethylating agents Elsevier decitabine Elsevier chemotherapy Elsevier azacitidine Elsevier Santini, Valeria oth Enthalten in Elsevier A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV026207648 volume:26 year:2013 number:4 pages:411-419 extent:9 https://doi.org/10.1016/j.beha.2013.09.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 26 2013 4 411-419 9 045F 610 |
| allfields_unstemmed |
10.1016/j.beha.2013.09.010 doi GBVA2013005000001.pica (DE-627)ELV038619857 (ELSEVIER)S1521-6926(13)00058-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Adès, Lionel verfasserin aut Hypomethylating agents and chemotherapy in MDS 2013transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). hypomethylating agents Elsevier decitabine Elsevier chemotherapy Elsevier azacitidine Elsevier Santini, Valeria oth Enthalten in Elsevier A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV026207648 volume:26 year:2013 number:4 pages:411-419 extent:9 https://doi.org/10.1016/j.beha.2013.09.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 26 2013 4 411-419 9 045F 610 |
| allfieldsGer |
10.1016/j.beha.2013.09.010 doi GBVA2013005000001.pica (DE-627)ELV038619857 (ELSEVIER)S1521-6926(13)00058-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Adès, Lionel verfasserin aut Hypomethylating agents and chemotherapy in MDS 2013transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). hypomethylating agents Elsevier decitabine Elsevier chemotherapy Elsevier azacitidine Elsevier Santini, Valeria oth Enthalten in Elsevier A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV026207648 volume:26 year:2013 number:4 pages:411-419 extent:9 https://doi.org/10.1016/j.beha.2013.09.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 26 2013 4 411-419 9 045F 610 |
| allfieldsSound |
10.1016/j.beha.2013.09.010 doi GBVA2013005000001.pica (DE-627)ELV038619857 (ELSEVIER)S1521-6926(13)00058-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Adès, Lionel verfasserin aut Hypomethylating agents and chemotherapy in MDS 2013transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). hypomethylating agents Elsevier decitabine Elsevier chemotherapy Elsevier azacitidine Elsevier Santini, Valeria oth Enthalten in Elsevier A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV026207648 volume:26 year:2013 number:4 pages:411-419 extent:9 https://doi.org/10.1016/j.beha.2013.09.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 26 2013 4 411-419 9 045F 610 |
| language |
English |
| source |
Enthalten in A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations Amsterdam [u.a.] volume:26 year:2013 number:4 pages:411-419 extent:9 |
| sourceStr |
Enthalten in A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations Amsterdam [u.a.] volume:26 year:2013 number:4 pages:411-419 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Informatik: Allgemeines Theoretische Nachrichtentechnik |
| institution |
findex.gbv.de |
| topic_facet |
hypomethylating agents decitabine chemotherapy azacitidine |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations |
| authorswithroles_txt_mv |
Adès, Lionel @@aut@@ Santini, Valeria @@oth@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
ELV026207648 |
| dewey-sort |
3610 |
| id |
ELV038619857 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV038619857</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625222746.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.beha.2013.09.010</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013005000001.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV038619857</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1521-6926(13)00058-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">590</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">070</subfield><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LING</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">53.71</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Adès, Lionel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypomethylating agents and chemotherapy in MDS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment).</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">hypomethylating agents</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">decitabine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">azacitidine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santini, Valeria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV026207648</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:411-419</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.beha.2013.09.010</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-LING</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-BBI</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.00</subfield><subfield code="j">Informatik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">53.71</subfield><subfield code="j">Theoretische Nachrichtentechnik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2013</subfield><subfield code="e">4</subfield><subfield code="h">411-419</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Adès, Lionel |
| spellingShingle |
Adès, Lionel ddc 610 ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier hypomethylating agents Elsevier decitabine Elsevier chemotherapy Elsevier azacitidine Hypomethylating agents and chemotherapy in MDS |
| authorStr |
Adès, Lionel |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV026207648 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 590 - Animals (Zoology) 070 - News media, journalism & publishing 004 - Data processing & computer science |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Hypomethylating agents and chemotherapy in MDS hypomethylating agents Elsevier decitabine Elsevier chemotherapy Elsevier azacitidine Elsevier |
| topic |
ddc 610 ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier hypomethylating agents Elsevier decitabine Elsevier chemotherapy Elsevier azacitidine |
| topic_unstemmed |
ddc 610 ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier hypomethylating agents Elsevier decitabine Elsevier chemotherapy Elsevier azacitidine |
| topic_browse |
ddc 610 ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier hypomethylating agents Elsevier decitabine Elsevier chemotherapy Elsevier azacitidine |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
v s vs |
| hierarchy_parent_title |
A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations |
| hierarchy_parent_id |
ELV026207648 |
| dewey-tens |
610 - Medicine & health 590 - Animals (Zoology) 070 - News media, journalism & publishing 000 - Computer science, knowledge & systems |
| hierarchy_top_title |
A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV026207648 |
| title |
Hypomethylating agents and chemotherapy in MDS |
| ctrlnum |
(DE-627)ELV038619857 (ELSEVIER)S1521-6926(13)00058-3 |
| title_full |
Hypomethylating agents and chemotherapy in MDS |
| author_sort |
Adès, Lionel |
| journal |
A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations |
| journalStr |
A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science 000 - Computer science, information & general works |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
411 |
| author_browse |
Adès, Lionel |
| container_volume |
26 |
| physical |
9 |
| class |
610 610 DE-600 590 VZ 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Adès, Lionel |
| doi_str_mv |
10.1016/j.beha.2013.09.010 |
| dewey-full |
610 590 070 004 |
| title_sort |
hypomethylating agents and chemotherapy in mds |
| title_auth |
Hypomethylating agents and chemotherapy in MDS |
| abstract |
Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). |
| abstractGer |
Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). |
| abstract_unstemmed |
Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment). |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI |
| container_issue |
4 |
| title_short |
Hypomethylating agents and chemotherapy in MDS |
| url |
https://doi.org/10.1016/j.beha.2013.09.010 |
| remote_bool |
true |
| author2 |
Santini, Valeria |
| author2Str |
Santini, Valeria |
| ppnlink |
ELV026207648 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.beha.2013.09.010 |
| up_date |
2024-07-06T18:42:38.488Z |
| _version_ |
1803856231518961664 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV038619857</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625222746.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.beha.2013.09.010</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013005000001.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV038619857</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1521-6926(13)00058-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">590</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">070</subfield><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LING</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">53.71</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Adès, Lionel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypomethylating agents and chemotherapy in MDS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment).</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">hypomethylating agents</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">decitabine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">azacitidine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santini, Valeria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV026207648</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:411-419</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.beha.2013.09.010</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-LING</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-BBI</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.00</subfield><subfield code="j">Informatik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">53.71</subfield><subfield code="j">Theoretische Nachrichtentechnik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2013</subfield><subfield code="e">4</subfield><subfield code="h">411-419</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.401636 |